We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| BioXcel Therapeutics Inc | NASDAQ:BTAI | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.01 | 0.39% | 2.57 | 0.97 | 3.92 | 2.6701 | 2.56 | 2.60 | 147,562 | 05:00:11 |
From May 2019 to May 2024
Conference Call & Webcast DetailsDate/Time: Thursday, March 11, 2021, 8:30 AM Eastern TimeDomestic: 877-407-2985International: 201-378-4915
The webcast will be accessible* under "Events" on the News & Media page of the Company's website at www.bioxceltherapeutics.com.
ReplayDomestic: 877-660-6853International: 201-612-7415Conference ID: 13716684
*Replay available through at least March 25, 2021
BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel’s two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. For more information, please visit www.bioxceltherapeutics.com.
Contact Information:
BioXcel Therapeutics, Inc.www.bioxceltherapeutics.com
Investor Relations:Mary ColemanBioXcel Therapeutics, VP of Investment RelationsMColeman@bioxceltherapeutics.com1.475.238.6837
John GrazianoSolebury Troutjgraziano@soleburytrout.com1.646.378.2942
Media:
Julia DeutschSolebury Troutjdeutsch@soleburytrout.com1.646.378.2967
1 Year BioXcel Therapeutics Chart |
1 Month BioXcel Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
